Ovid公布下一代GABA氨基转移酶抑制剂Ov329积极的顶线结果,显示出强效抑制活性和潜在的同类最佳安全性特征

美股速递
Oct 03

Ovid Therapeutics Inc.公布了其下一代GABA氨基转移酶抑制剂Ov329的积极顶线结果,研究数据显示该药物具有强效的抑制活性,并展现出潜在的同类最佳安全性特征。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10